Turtle Cameron 4
4 · Spyre Therapeutics, Inc. · Filed Feb 4, 2026
Research Summary
AI-generated summary of this filing
Spyre (SYRE) CEO Turtle Cameron Sells 15,000 Shares
What Happened
Turtle Cameron, CEO of Spyre Therapeutics (SYRE), sold a total of 15,000 shares on February 2, 2026 in open-market/private sales, for aggregate proceeds of approximately $492,045. The sales consisted of 957 shares at a weighted average price of $31.82 (≈ $30,452) and 14,043 shares at a weighted average price of $32.87 (≈ $461,593). These were sales (not purchases), which are often routine executive liquidity events rather than an explicit bullish signal.
Key Details
- Transaction dates: February 2, 2026 (reported on Form 4 filed February 4, 2026). Filing appears timely (filed within the typical 2-business-day window).
- Prices and ranges: reported weighted averages $31.82 and $32.87; underlying trade prices ranged $31.42–$32.05 for one group and $32.48–$33.35 for the other. Reporting person can provide exact per-trade breakdown on request (per footnotes).
- 10b5-1 plan: At least one of the transactions was executed pursuant to a Rule 10b5-1 trading plan adopted June 20, 2025.
- Shares owned after transaction: Not specified in the provided excerpt. Footnotes indicate holdings include 145,198 shares that vest monthly over roughly one year (service-based) and 633 shares acquired via the company’s ESPP (Aug 15, 2024).
- Footnotes: F2/F5 note weighted-average pricing and ranges; F1 notes the 10b5-1 plan; F3/F4 describe items included in ownership counts.
Context
- Sales under a pre-established 10b5-1 plan are pre-scheduled and generally limit inferences about insider sentiment.
- These were straight sales (transaction code S). No option exercises, gifts, or tax-withhold events were reported in the provided excerpt.
- For more detail (exact per-trade prices, post-transaction holdings), consult the full Form 4 filing (Accession 0001758363-26-000005).
Insider Transaction Report
Form 4
Turtle Cameron
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
[F1][F2][F3][F4]2026-02-02$31.82/sh−957$30,452→ 671,583 total - Sale
Common Stock
[F1][F5][F3]2026-02-02$32.87/sh−14,043$461,593→ 657,540 total
Footnotes (5)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.
- [F2]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.42 to $32.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]Includes 145,198 shares of common stock that vest in monthly installments over approximately one year, subject to the continuing service of the Reporting Person on each vesting date.
- [F4]Includes 633 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on August 15, 2024.
- [F5]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.48 to $33.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
Signature
/s/ Heidy King-Jones, as Attorney-in-Fact|2026-02-04